Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Retavibart on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Retavibart is a long-acting antibody injection that protects babies against serious chest infections caused by respiratory syncytial virus (RSV). It was developed by Zhuhai Trinomab Pharmaceutical Co., Ltd. and is sold in China as 新多妥 (Xinduotuo). In research it was called TNM001.
China's National Medical Products Administration (NMPA) approved it in September 2026, after a priority review. It is approved for:
It is a prescription infection-prevention medicine and should be given under the care of a paediatrician or neonatologist.
RSV is a common seasonal virus. Most infants catch it in their first year, and in young babies it can spread to the lungs and lead to hospital care. Retavibart is a fully human monoclonal antibody, isolated from natural human immune cells, that locks on to the pre-fusion (Pre-F) form of the virus's F protein. This stops the virus from fusing with cells in the airways. Instead of waiting for the baby's own immune system to respond, the injection gives ready-made protection straight away. The company reports protection data for up to 270 days (about nine months) from one dose.
A phase 2b trial, published as a conference abstract in Open Forum Infectious Diseases (2026), included 751 infants with a median age of 2.5 months, including some born early or with heart disease. Compared with a placebo injection, one dose of retavibart cut lab-confirmed RSV chest infections needing medical care by 66.2% and RSV hospital admissions by 82.3% over about five months. In the 92 higher-risk babies, the reductions were 91.1% and 93.5%.
Trinomab reports that its phase 3 trial in healthy full-term and late-preterm infants also showed a significant fall in RSV chest infections, especially severe ones. Full phase 3 numbers had not been published in a journal at the time of writing.
The paediatrician decides the right timing for your baby based on the label and local RSV patterns.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Overall safety: in the phase 2b trial, the rates of side effects and of serious side effects were similar with retavibart and with placebo. No baby died and none left the trial because of a side effect. Babies were followed for safety for up to 240 days after the injection.
Limits of the evidence: the approved use is for infants in their first RSV season. Detailed phase 3 safety figures were not yet published in a journal, so the full Chinese prescribing information should guide use.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient's family or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit. Because RSV seasons are predictable, we suggest starting the request a few weeks before the planned injection date.
No. It is approved only in China. It has no CDSCO approval and is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it.
Families can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. We also arrange other preventive anti-infective imports, such as Prevymis.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. It is stored and shipped as directed on the pack, using temperature-controlled shipping to the treating hospital or clinic. We time each delivery to the baby's planned injection date. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Families across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital or clinic on a valid paediatrician's prescription.
Paediatricians and neonatal units in Delhi can send us the prescription; our New Delhi dispatch point keeps transit short.
We plan delivery around the baby's injection appointment so the dose is ready on the day.
Parents and paediatricians in Bangalore receive a written quote before anything is ordered.
Deliveries go directly to the hospital or clinic that will give the injection.
Neonatal units in Hyderabad can request it for a named baby, with updates at each step.
Shipments to Kolkata and the eastern states travel under controlled temperature conditions.
Families in Pune can use the same documented import route through their paediatrician.
The paediatrician can share the prescription and birth details with us to begin the import.
Babies cared for at hospitals in Vellore can have the injection delivered straight to the hospital.
Serves families from Punjab, Haryana and Himachal Pradesh, with delivery to the treating hospital.
We coordinate delivery to children's hospitals and clinics across Uttar Pradesh.
Families across Kerala can receive the injection at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
